Back to results
US 2010/0062013 A1Published application
Cancer antigen peptides derived from wt1
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorHaruo SUGIYAMA
Life of this patent
Estimating the term…
Abstract
The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.
Claims18
A method for treating or preventing cancer in a HLA-A26 positive patient, comprising administering an effective amount of a peptide as set froth in any one of SEQ ID NOs:
- 2, 8 and 9 to a HLA-A26 positive patient.
A method for treating or preventing cancer in a HLA-A26 positive patient, comprising administering an effective amount of a peptide as set froth in any one of SEQ ID NOs:
- 2, 8, 9, 10, 11, 12, 13, 14, and 15 to a HLA-A26 positive patient.
Dependencies are inferred from the claim text.